Biomarkers of Bone Resorption in Metastatic Prostate Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2010 by University of Aberdeen
Sponsor:
Collaborator:
NHS Grampian
Information provided by:
University of Aberdeen
ClinicalTrials.gov Identifier:
NCT01233557
First received: November 2, 2010
Last updated: NA
Last verified: November 2010
History: No changes posted
  Purpose

Biomarkers of bone resorption will be measured in the blood of patients with bone metastases from prostate cancer during the course of their illness. Changes in these biomarkers will be correlated with the patient's treatment with antiandrogen therapy and bisphosphonates and the response and/or progression of their cancer. It is hoped that serial measurement of these biomarkers may allow therapeutic monitoring in the future with successful individualisation of bisphosphonate therapy for metastatic prostate cancer.


Condition
Metastatic Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Measurement of Biomarkers of Bone Resorption in Patients With Hormone Sensitive Bone Metastases From Prostate Cancer Treated With Antiandrogen Therapy and Bisphosphonates

Resource links provided by NLM:


Further study details as provided by University of Aberdeen:

Estimated Enrollment: 40
Study Start Date: September 2010
Estimated Study Completion Date: August 2015
Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
Bone Metastases

  Eligibility

Ages Eligible for Study:   40 Years to 80 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

men with hormone sensitive prostate cancer with bone metastases

Criteria

Inclusion Criteria:

  • prostate cancer with bone metastases
  • hormone sensitive

Exclusion Criteria:

  • inadequate renal function
  • ongoing dental problems
  • previous bisphosphonate therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01233557

Contacts
Contact: Donald Bissett, M.D. 01224551273 donald.bissett@nhs.net

Locations
United Kingdom
Aberdeen Royal Infirmary Recruiting
Aberdeen, United Kingdom, AB25 2ZN
Contact: Donald Bissett, M. D.    01224 551273 ext 51273    donald.bissett@nhs.net   
Sponsors and Collaborators
University of Aberdeen
NHS Grampian
Investigators
Principal Investigator: Donald Bissett, M.D. NHS Grampian
  More Information

No publications provided

Responsible Party: Dr Donald Bissett, NHS Grampian
ClinicalTrials.gov Identifier: NCT01233557     History of Changes
Other Study ID Numbers: 10/S0802/36
Study First Received: November 2, 2010
Last Updated: November 2, 2010
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Bone Resorption
Prostatic Neoplasms
Bone Diseases
Musculoskeletal Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on August 18, 2014